Newrotex Analysis
What is Newrotex?
Newrotex develops a silk-based peripheral nerve conduit to repair nerve injuries without requiring autografts. The technology uses luminal silk fibres to guide axon regeneration and a biocompatible tube to support vascularisation. The solution is designed for immediate treatment, reducing surgery time and eliminating donor tissue risks. The company has received regulatory approval for a first-in-human trial in Panama and is advancing toward pivotal trials in the U.S. and Europe.
Location
Oxford, United Kingdom
Employees
1-10
Founded
2019
Product Features & Capabilities
- SilkAxons™ nerve guide for peripheral nerve repair
- Luminal silk fibres for axon guidance
- Biocompatible tubular sheath for vascularisation
- Off-the-shelf nerve conduit in multiple lengths and diameters
Use Cases
Repair peripheral nerve injuries up to 10cm gap; Replace autografts in trauma or surgical nerve damage cases; Enable immediate treatment without donor tissue; Reduce surgery time and complications from donor site morbidity; Support axonal regeneration in large nerve gaps
Other Considerations
Received regulatory approval for first-in-human trial in Panama; Selected as a finalist for MedTech Innovator 2023 Value Award; Won prize at ASPS 92nd Annual Meeting; Selected as runner-up in ASPS Plastic Surgery Accelerator competition; Preclinical studies show superior axonal regeneration compared to autografts; Targets 1.5 million annual nerve injury operations globally
See something that needs updating? Suggest edits to this profile.